{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:16:30Z","timestamp":1774898190288,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12328-020-01306-1","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:04:06Z","timestamp":1609632246000},"page":"645-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4363-9536","authenticated-orcid":false,"given":"Yoshiaki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Sunagozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyabi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkei","family":"Hasatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,2]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1306_CR2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/hepr.13243","volume":"49","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatol Res. 2019;49:111\u20137.","journal-title":"Hepatol Res"},{"key":"1306_CR3","first-page":"5389","volume":"6","author":"EM Aibek","year":"2014","unstructured":"Aibek EM, Alaa MA, Maliha K, Aram B. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors. 2014;6:5389.","journal-title":"Rare Tumors"},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3\u201311.","journal-title":"Br J Haematol"},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000487148","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer. 2018;7:1\u201319.","journal-title":"Liver Cancer"},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ncponc0581","volume":"3","author":"E Rampello","year":"2006","unstructured":"Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol. 2006;3:438\u201347.","journal-title":"Nat Clin Pract Oncol"},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.3748\/wjg.15.4464","volume":"15","author":"WS Huang","year":"2009","unstructured":"Huang WS, Yang CH. Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol. 2009;15:4464\u20136.","journal-title":"World J Gastroenterol"},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2169\/internalmedicine.49.3153","volume":"49","author":"S Joshita","year":"2010","unstructured":"Joshita S, Yoshizawa K, Sano K, et al. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome. Intern Med. 2010;49:991\u20134.","journal-title":"Intern Med"},{"key":"1306_CR9","unstructured":"Imam SZ, Zahid MF, Maqbool MA. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 2018."},{"key":"1306_CR10","unstructured":"Lenvima capsule (hepatocellular carcinoma) List of severe adverse events. Eisai. Available at: https:\/\/medical.eisai.jp\/products\/LEN_C4_H\/ Accessed April 13, 2020."},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jceh.2018.04.002","volume":"9","author":"SK Sahu","year":"2019","unstructured":"Sahu SK, Chawla YK, Dhiman RK, et al. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol. 2019;9:245\u201356.","journal-title":"J Clin Exp Hepatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-020-01306-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T08:10:05Z","timestamp":1670659805000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-020-01306-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01306-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,2]]},"assertion":[{"value":"20 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yoshiaki Shimizu, Hajime Sunagozaka, Koki Yamagata, Hirokazu Hirai, Miyabi Miura, Yuichiro Yonemoto, Yoshihide Naito, Kenkei Hasatani, Jun Yoshikawa, Hiroyuki Aoyagi and Shuichi Kaneko declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}